Navigation Links
IDM Pharma Provides Update of Product Pipeline and Announces Plans to Evaluate Strategic Alternatives for the Company
Date:12/14/2007

nd to all of the questions and requests for additional information received from FDA, the Company now anticipates it will likely take until the second half of 2008 to prepare the amendment to the new drug application (NDA) for L-MTP-PE.

Given the significant additional time and cost that would need to be incurred in order to collect the patient data and respond to regulatory agency comments on the filings for L-MTP-PE, the Company's board of directors authorized management to work with the Company's investment bank, JMP Securities, to evaluate the Company's research and development programs, including related assets and costs, and strategic alternatives available to the Company.

"We, along with key opinion leaders in the United States and Europe, continue to strongly believe in the survival benefit offered by L-MTP-PE in osteosarcoma patients, a devastating disease where there hasn't been a treatment advance in more than 20 years," said Timothy P. Walbert, president and chief executive officer, IDM Pharma. "Based on the current status of the lead program and an evaluation of the timing, potential costs and risks involved in continuing with current clinical plans, we believe it is prudent to manage our cash burn at this time and to pursue strategic alternatives that would potentially preserve the value of our lead program assets without undue risks."

Additional Clinical Updates

UVIDEM(R)

The next planned step in the UVIDEM development program is a Phase 2, open-label, randomized study of UVIDEM designed to evaluate patients with in-transient or low volume metastatic melanoma in the next 60 days. Patients will receive UVIDEM or UVIDEM plus low-dose cyclophosphamide and treatment(s) will continue for a maximum of two years. The primary endpoint will be progression-free survival and secondary endpoints include tumor response, safety and immune monitoring. The study is designed to enroll 82 patients at sites in the United States and Eur
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)...  Every day, their baby stopped breathing, his collapsed bronchus ... April and Bryan Gionfriddo watched helplessly, just ... "Quite a few doctors said he had a good chance ... Gionfriddo , about her now 20-month-old son, Kaiba. "At ... would take it and run with it." They ...
(Date:5/23/2013)... , May 23, 2013  Spring Bank Pharmaceuticals, Inc., ... of viral infections, today announced that it has initiated ... its investigational, once daily, oral therapy for the treatment ... HCV-infected patients and is designed to assess both the ... is a first-in-class drug for the treatment of chronic ...
(Date:5/23/2013)... ALBUQUERQUE, N.M. , May 23, 2013  Net ... in the telemedicine market, announced today the company has ... a telemedicine staffing company based in Huntsville, ... agency that specializes in the staffing and recruitment of ... upon completion of the final agreement, which is expected ...
Breaking Medicine Technology:Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 2Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 3Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 4Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 2Net Medical Xpress Announces Acquisition of Telemedicine Staffing Company 3
... Dune Medical Devices, Inc. today announced that the ... for filing the company,s Pre-Market Approval (PMA) application ... that the PMA application was sufficiently complete and ... MarginProbe represents a breakthrough technology that may offer ...
... WASHINGTON, May 16, 2011 During Older ... encourages America,s seniors to connect with their pharmacist to ... and available wellness opportunities. As the most accessible health ... to discuss many of the issues that arise due ...
Cached Medicine Technology:FDA Formally Accepts Dune Medical's MarginProbe™ System Pre-Market Approval (PMA) Application and Grants Expedited Review Status 2APhA Encourages Seniors to Connect with Their Pharmacist to Increase Wellness and Medication Knowledge 2APhA Encourages Seniors to Connect with Their Pharmacist to Increase Wellness and Medication Knowledge 3
(Date:5/23/2013)... May 23, 2013 Today, Zane Benefits, ... mandate . Zane Benefits, which provides comprehensive and flexible ... leader in defined contribution plans and ... a common question from employees is “does my employer ... website, not necessarily. The health care reform law, called ...
(Date:5/23/2013)... Mann HealthDay Reporter , , THURSDAY, May 23 ... take to help treat hip and knee osteoarthritis may ... for developing glaucoma, a small new study of older ... an increase of intraocular pressure (IOP) or pressure inside ... leading causes of blindness. In the ...
(Date:5/23/2013)... journal Science published an article about bexarotene ... an important starting point for further Alzheimer,s research. The ... at VIB and KU Leuven in collaboration with ... and scientists at Janssen Pharmaceutica, Beerse, also tested this ... results were different, as were those of two American ...
(Date:5/23/2013)... about to be tested in a clinical trial by ... for Alzheimer,s disease has failed to work with the ... according to results of a study by University of ... neuroscience affiliated with the Evelyn F. and William L. ... the importance of verifying promising research results before investing ...
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 Dr. ... her new charitable organization in Orange County, OCCares , ... in Orange County. The event details are as follows: ... Orangewood Academy Auditorium, 13732 Clinton Street, Garden Grove, CA 92843 ... pop crossover music by Christian vocalists Charmaine & Jonathan Thulin. ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on the Employer Mandate 2Health News:Zane Benefits Publishes New Information on the Employer Mandate 3Health News:Glucosamine Supplements Tied to Risk of Eye Condition 2Health News:Glucosamine Supplements Tied to Risk of Eye Condition 3Health News:New insights contradict promising Alzheimer's research 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 3Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 2Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 3
... was more rapid afterward, study finds , , TUESDAY, Oct. ... education seems to delay the onset of dementia, but ... a new study finds. , The findings confirm ... with more education have some kind of brain "reserve" ...
... dont dispute the important role that diet and activity ... eating habits and a less active lifestyle fully explain ... That question has led some researchers to ask whether ... In the October issue of Mayo Clinic Proceedings, researcher ...
... calls for greater collaboration across Europe on research in ... in improved and cost-effective healthcare, the ESF says, but ... and industry if Europe is to realise the full ... The call comes in a new ESF Science Policy ...
... LA JOLLA, Calif., Oct. 23 Immunosyn,Corporation (OTC Bulletin ... as the company,s Chief Executive Officer, President and,board member. ... role at Immunosyn and help,shape the company,s success. I ... life for millions of people who suffer from painful ...
... of fatigue might find some relief through regular exercise ... a new review. , Fatigue is one of ... those undergoing treatment with radiation and chemotherapy. According to ... cancer treatment experience fatigue that can range from mild ...
... McKusick-Nathans Institute of Genetic Medicine today are releasing newly ... Hopkins data, coordinated with a similar data release from ... hereditary factors and speed the understanding of autism by ... look to date at the genetic variation patterns in ...
Cached Medicine News:Health News:Dementia in More Educated Hits Later But Harder 2Health News:Mayo Clinic Proceedings article explores possible link between obesity and viral infections 2Health News:Mayo Clinic Proceedings article explores possible link between obesity and viral infections 3Health News:Improving Europe's image 2Health News:Immunosyn Corporation Names Stephen Ferrone as CEO 2Health News:Exercise and psychological counseling could ease cancer-related fatigue 2Health News:Exercise and psychological counseling could ease cancer-related fatigue 3Health News:Hopkins researchers release genome data on autism 2
... Hold & Support A Dropping Lens To Safely ... Phacoemulsification To ,Continue. Can Support Multiple ... Cyclodialysis Spatula To Reach Into The ... Lens Fragments With One Instrument. ,A 23g ...
... In-Line Footplates Are Turned 90 Degrees ... Diamond Blade While Incising Tissue. ,Special Mirror-Polished ... Depth Penetration.,Pre-Set Blade Extension Settings Of ... And Full Extension.,1mm Wide Snub Nose ...
... 0.1mm Pierce Tip Opening Is Designed ... The Need For A Separate Cystotome. The 11mm ... Without Elevating The Incision.,The Distal Jaws Have Platforms, ... To Prevent Inadvertent Pick Up Of Iris. The ...
2.5V Halogen source, fiber-optic delivery, 2.5X magnification....
Medicine Products: